TG Therapeutics
TGTX
247 hedge funds and large institutions have $5.19B invested in TG Therapeutics in 2020 Q4 according to their latest regulatory filings, with 83 funds opening new positions, 79 increasing their positions, 57 reducing their positions, and 16 closing their positions.
419% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 16
123% more capital invested
Capital invested by funds: $2.33B → $5.19B (+$2.86B)
100% more funds holding in top 10
Funds holding in top 10: 5 → 10 (+5)
39% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 57
36% more funds holding
Funds holding: 181 → 247 (+66)
28% more call options, than puts
Call options by funds: $138M | Put options by funds: $107M
3.27% more ownership
Funds ownership: 69.24% → 72.51% (+3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$131M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$118M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$54.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$45.6M |
| 5 |
Alkeon Capital Management
New York
|
+$44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$42.8M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
-$40.2M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$30.4M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$18.9M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$16.6M |
TGTX Hedge Fund Activity: Q4 2020 in Review
247 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2020, worth a combined $5.19B — up 123% from $2.33B a quarter earlier.
Buyers outnumbered sellers: 83 funds opened new TGTX positions and 16 closed out — a net gain of 67 holders — while 79 added to existing stakes and 57 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $131M. The largest seller was Great Point Partners, exiting entirely with an estimated $42.8M sold.
- 247 institutional investors held TG Therapeutics (TGTX) as of Q4 2020, up from 181 in Q3 2020.
- Funds reported $5.19B of TG Therapeutics stock for Q4 2020, up 123% quarter-over-quarter.
- 83 funds opened new TG Therapeutics positions in Q4 2020 and 16 closed out, a net change of +67 holders.
- The largest TG Therapeutics buyer in Q4 2020 was Fidelity Investments, an estimated $131M added.
- The largest TG Therapeutics seller in Q4 2020 was Great Point Partners, an estimated $42.8M sold.
Based on aggregated 13F filings for Q4 2020.